Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Read our news
-
Articles October 3, 2024HTL Biotechnology will launch its White Paper at CPHI Milan!
We are excited to announce that the HTL Biotechnology team will be attending CPHI Milan and on this occasion, we will be launching our White Paper to celebrate 90 years of discovery of Hyaluronic Acid!
-
Press releases October 1, 2024New Certification for HTL Biotechnology
We are proud to announce that HTL Biotechnology has recently received Halal certification for two of our key products: DNA and HANa. Discover our press release.
-
Articles July 5, 2024HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.
-
Articles June 21, 2024HTL Biotechnology at CPHI China 2024
CPHI China is one of Asia’s leading Pharma events for trading and networking with 3,500+ exhibitors and 90,000+ professionals from the pharmaceutical industry,
-
Articles June 13, 2024Discover our Quality Policy
At HTL Biotechnology, we believe in going beyond together to achieve the highest quality standards.
-
Articles June 5, 2024National Bioproduction and Biomedicine Day (TVR report)
On the occasion of the first National Bioproduction and Biomedicine Day, which took place on the last 5th july, we were very proud to welcome a TVR journalist in our Javené site for an exclusive report.
-
Articles June 5, 2024New Ecovadis Gold label 2024
We are delighted to announce that HTL Biotechnology has once again been awarded the EcoVadis Gold 2024 label for its Corporate Social Responsibility (CSR) performance!
-
Press releases June 3, 2024BIOPHTA 6.5 million Euros Seed Funding
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage.
-
Press releases May 6, 2024Acquisition of the Modern Meadow’s human recombinant collagen platform for beauty and biomedical applications
HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisition includes Modern Meadow’s platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3).
-
Articles April 16, 2024HTL Biotechnology at In-cosmetics Global Congress in Paris
As every year, the In-Cosmetics Global Congress returns to Paris, with top industry leaders and experts gathering under one roof.
This event promises opportunities and insights into the future of Cosmetics. -
Articles April 9, 2024France BioLead Membership
France BioLead structures, pilots, supports and promotes the French biomanufacturing sector.
-
Articles March 28, 2024Attending AMWC in Monaco
AMWC, the Aesthetic & Anti-Aging Medicine World Congress in Monaco.